Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
V-type proton ATPase 116 kDa subunit a3 (TCIRG1) is an essential membrane protein acting as the a3 subunit within the larger vacuolar H+-ATPase (V-ATPase) complex. V-ATPases are responsible for pumping protons across intracellular and extracellular membranes, regulating pH and acidifying vesicular compartments. The a3 subunit is particularly critical in osteoclasts, where it creates an acidic environment necessary for bone matrix dissolution and normal bone remodeling. TCIRG1’s variant TIRC7, arising by alternative splicing, plays a distinct role as a regulator in T cells, mediating immune response and cell apoptosis via interaction with HLA-DRα2. Mutations in TCIRG1 are directly linked to severe infantile osteopetrosis and have been implicated in immune dysregulation. Due to its central roles, the target is of interest in bone resorption disorders and potentially in immune-related therapeutic strategies.
Inhibition of proton transport—blocking acidification in vesicles or extracellular spaces, leading to failure of bone resorption or altered cellular homeostasis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on V-type proton ATPase 116 kDa subunit a3 (TCIRG1).